Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 80

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 80
---
 Retirement Date, which totaled $25,000; and (vi) certain other benefits, including change of control benefits (which lapsed on the Retirement Date), expense reimbursement and payment of accrued vacation. The Retirement Agreement also contained customary provisions relating to indemnification, continued cooperation with the Company, and certain non-disparagement covenants. The Company and Mr. Stack also entered into a Consulting Agreement, effective September 1, 2024, pursuant to which Mr. Stack will provide transition services to the Company from September 1, 2024 until August 31, 2025. Pursuant to the Consulting Agreement, Mr. Stack will receive $20,000 per month for up to 15 hours of transition services each month during the Consulting Period. A total of $80,000 was earned by Mr. Stack under the Consulting Agreement during 2024. Charles A. Reinhart, III Departure On February 26, 2024, the Company and Charles A. Reinhart, III, the Company’s former Chief Financial Officer, agreed that he would depart the Company, effective September 30, 2024 (the “Transition Date”).

86 | investor.pacira.com

TABLE OF CONTENTS Executive Compensation In connection with his departure and the services Mr. Reinhart will provide during the transition period, the Company and Mr. Reinhart agreed, subject to execution and non-revocation of a customary release of claims against the Company, that Mr. Reinhart will be entitled to: (i) continued payment of his base salary either for nine months following the Transition Date, which payments will total $372,675; (ii) eligibility for a pro-rated cash targeted annual incentive bonus for 2024, subject to certain conditions, which payment totaled $172,258; (iii) eligibility for a cash bonus payment under the Company’s long-term incentive program for the 2021 performance period following the completion of the three-year vesting period, which ran through December 31, 2024, subject to certain conditions, which payment totaled $165,030; (iv) eligibility for the Company’s 2024 annual equity grant, subject to certain conditions, which was planned at 25% of the intended targeted value and had a grant-date fair value of $350,470; (v) immediate vesting of the portion of Mr. Reinhart’s outstanding unvested stock options and time-based restricted stock units that would have become vested during the nine-month period following